CSPC: Company enters into exclusive licensing agreement with MADRIGAL for SYH2086 with advance payment of USD 120 million
2025-07-30 09:03:17
On July 30th, 01093.HK announced that the Group has entered into an exclusive license agreement with Madrigal Pharmaceuticals, Inc. for the global development, production and commercialization of the Group's oral small molecule activating glucagon-like peptide-1 receptor agonist SYH2086. Agree to grant Madrigal the exclusive license to develop, produce and commercialize SYH2086 worldwide, while retaining the Group's interests in the development and sale of other oral small molecule GLP-1 receptor agonist products in China. The Group is entitled to receive up to $2.075 billion in total consideration, including up-front payment of $120 million, up to $1.955 billion in potential development, regulatory and commercial milestone payments, and up to double-digit sales commission based on annual net sales of SYH2086.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
